ISRCTN15068483已完成Unknown
Double-blind placebo-controlled clinical study to evaluate the effect of supplementation with Phenixun Shield® during 8 weeks on skin protection immediately after exposure to ultraviolet radiation in Asian subjects
INNOVATION LABO SCIENCES Co., Ltd0 个研究点目标入组 60 人开始时间: 2023年8月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Healthy non-smoker Asian female subjects between aged 25 and 55 years (inclusive) old
- •2. Fitzpatrick skin type II - IV
- •3. Individuals of childbearing potential use an acceptable method of contraception throughout the study
- •4. Subjects must be stable on any medication they are taking for at least 30 days
- •5. Willing to give written informed consent and willing to comply with the trial protocol
- •6. Ability to understand the risks/benefits of the protocol
- •7. Subject should be available for the duration of the study period (8 weeks)
排除标准
- •1. Photosensitivity disorders
- •2. Condition and/or disease of the skin that the Investigator deems inappropriate for participation
- •3. Women who are nursing, pregnant, or planning to become pregnant during the study
- •4. Pre-existing or dormant dermatologic conditions which in the opinion of the Investigator could interfere with the outcome of the study
- •5. Regular consumption or application of any supplement (herbal, vitamin, etc)
- •6. Skin conditions including atopic dermatitis
- •7. Significant disease history of heart failure, dyslipidemia, diabetes, or uncontrolled hypertension
- •8. Risk of food allergy
- •9. Extreme skin condition changes caused by menstruation or irregular menstruation
- •10. Currently participating in another facial usage study or have participated in a clinical trial within 4 weeks prior to inclusion into the study
- •11. Planned surgeries and/or invasive medical procedures during the course of the study
- •12. Hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to study entry or who plan on starting, stopping, or changing doses of HRT or hormones for birth control during the study
- •13. Facial sunburn or excessively tanned facial skin or that are not willing to avoid daily sun exposure on the face and the use of tanning beds or sunless tanning products for the duration of the study
- •14. Currently taking or have taken oral or topical probiotics or antibiotics within the last 30 days
- •15. Subjects having a history of psychiatric disorder that may impair the ability of subjects to provide written informed consent
- •16. Patients who have completed participation in any other clinical trial during the past 3 month
研究者
相似试验
已完成
Unknown
A study to evaluate the effect of ETAZEO supplementation on sleep qualityISRCTN60603080INNOVATION LABO Sciences Co., Ltd40
已完成
Unknown
A study to evaluate the effect of Astrobiome® supplementation in inflammation and insulin resistance in type 2 diabetesPrevention of inflammation in patients with diabetesNutritional, Metabolic, EndocrineISRCTN15628064INNOVATION LABO Sciences Co., Ltd50
进行中（未招募）
Unknown
Efficacy of an organic pomegranate polyphenol complex (VIQUA®) in type 1 primary osteoporosis in post-menopausal womePrevention of osteoporosis in postmenopausal womenMusculoskeletal DiseasesISRCTN13473651INNOVATION LABO Sciences Co., Ltd60
进行中（未招募）
1 期
Double-blind, placebo-controlled clinical trial to determine the effect of Patiromer on vascular function and its relationship with mineral metabolism parametersChronic kindney diseaseCTIS2023-503941-69-00Fundacion Para La Investigacion Biomedica De Cordoba40
已完成
不适用
A double-blind placebo-controlled clinical trial of botulinum toxin type A injection therapy in patients with Japanese cedar pollinosisJapanese cedar pollinosisJPRN-UMIN000001657Department of Otorhinolaryngology, Head and Neck Surgery Faculty of Medicine, University of Yamanash32